Security Snapshot

Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) Institutional Ownership

CUSIP: 221015100

13F Institutional Holders and Ownership History from Q1 2016 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

125

Shares (Excl. Options)

46,682,919

Price

$7.70

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
CRVS on Nasdaq
Shares outstanding
91,091,040
Price per share
$16.08
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
46,682,919
Total reported value
$359,443,900
% of total 13F portfolios
0%
Share change
+5,032,183
Value change
+$38,829,151
Number of holders
125
Price from insider filings
$16.08
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • CRVS - Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 221015100.
  • 125 institutions reported positions in Q4 2025.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 125 to 161 between Q4 2025 and Q1 2026.
  • Reported value moved from $359,443,900 to $1,018,372,597.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 125 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 221015100?
CUSIP 221015100 identifies CRVS - Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 10% -16% $66,290,001 -$9,057,756 8,609,091 -12% ORBIMED ADVISORS LLC 23 Jan 2026
Sirenia Capital Management LP 7.5% $101,657,601 6,831,828 Sirenia Capital Management LP 31 Mar 2026
MILLER RICHARD A MD 7.8% +1.2% $40,653,959 +$5,781,901 6,085,922 +17% Richard A. Miller 31 Dec 2025
BlackRock, Inc. 6.4% +20% $78,823,777 +$20,076,866 5,387,818 +34% BlackRock, Inc. 31 Mar 2026
ADAMS STREET PARTNERS LLC 3.9% $25,222,243 3,275,616 Adams Street Partners, LLC 23 Jan 2026

As of 31 Dec 2025, 125 institutional investors reported holding 46,682,919 shares of Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS). This represents 51% of the company’s total 91,091,040 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) together control 47% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ORBIMED ADVISORS LLC 7.9% 7,165,006 0% 1.2% $55,170,546
BlackRock, Inc. 5.6% 5,056,361 +7.3% 0% $38,933,979
VANGUARD GROUP INC 4.3% 3,873,482 +12% 0% $29,825,811
MORGAN STANLEY 3.9% 3,567,908 +478% 0% $27,472,892
ADAMS STREET PARTNERS LLC 3.6% 3,275,616 0% 9.6% $25,222,243
Point72 Asset Management, L.P. 3.2% 2,875,000 -55% 0.03% $22,137,500
STATE STREET CORP 3.1% 2,788,223 +177% 0% $21,469,317
MPM BIOIMPACT LLC 3% 2,743,671 2.4% $21,126,267
Vivo Capital, LLC 2.5% 2,234,566 0% 1.1% $17,206,158
GEODE CAPITAL MANAGEMENT, LLC 1.6% 1,473,026 +1.1% 0% $11,345,051
Foresite Capital Management VI LLC 1.5% 1,381,233 -20% 3.2% $10,635,494
DCF Advisers, LLC 0.8% 729,000 1.9% $5,613,300
PERCEPTIVE ADVISORS LLC 0.76% 692,441 -52% 0.1% $5,331,796
MILLENNIUM MANAGEMENT LLC 0.76% 688,770 0% $5,303,529
GOLDMAN SACHS GROUP INC 0.61% 553,327 +24% 0% $4,260,618
Logos Global Management LP 0.55% 500,000 0.26% $3,850,000
ADAR1 Capital Management, LLC 0.51% 465,875 0.27% $3,587,238
RTW INVESTMENTS, LP 0.49% 447,607 -83% 0.03% $3,446,574
NORTHERN TRUST CORP 0.47% 429,771 -7.9% 0% $3,309,237
SPHERA FUNDS MANAGEMENT LTD. 0.45% 407,709 0% 0.66% $3,139,359
BARCLAYS PLC 0.43% 394,766 +28% 0% $3,039,698
JANE STREET GROUP, LLC 0.42% 378,297 +456% 0% $2,912,886
WELLINGTON MANAGEMENT GROUP LLP 0.35% 314,683 +75% 0% $2,423,059
BANK OF AMERICA CORP /DE/ 0.26% 236,495 +56% 0% $1,821,011
MARSHALL WACE, LLP 0.24% 216,248 0% $1,665,111

Institutional Holders of Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 69,646,120 $1,018,372,597 +$363,034,281 $14.63 161
2025 Q4 46,682,919 $359,443,900 +$38,829,151 $7.70 125
2025 Q3 41,673,686 $307,002,895 +$4,353,875 $7.37 101
2025 Q2 41,781,497 $167,123,225 +$27,653,733 $4.00 92
2025 Q1 36,268,523 $115,333,082 -$7,370,970 $3.18 87
2024 Q4 37,723,156 $201,818,514 +$34,704,752 $5.35 85
2024 Q3 30,026,264 $158,538,176 +$12,733,385 $5.28 61
2024 Q2 27,591,708 $50,216,835 +$17,655,345 $1.82 46
2024 Q1 17,899,766 $31,860,771 -$2,279,392 $1.78 46
2023 Q4 19,183,314 $33,762,501 +$90,871 $1.76 46
2023 Q3 19,186,334 $28,011,450 -$1,230,958 $1.46 52
2023 Q2 19,491,995 $44,633,999 +$707,708 $2.29 51
2023 Q1 20,767,710 $18,897,208 -$183,902 $0.91 35
2022 Q4 21,363,573 $18,157,963 -$606,364 $0.85 38
2022 Q3 22,082,952 $18,073,081 -$3,458,421 $0.82 38
2022 Q2 25,594,950 $25,339,212 -$3,279,778 $0.99 39
2022 Q1 27,387,121 $44,913,000 -$1,201,434 $1.64 52
2021 Q4 27,678,421 $66,701,000 -$7,831,144 $2.41 58
2021 Q3 28,180,241 $136,388,000 +$22,907,893 $4.84 55
2021 Q2 23,673,230 $63,207,000 +$8,569,595 $2.67 44
2021 Q1 20,393,400 $62,807,000 +$12,093,812 $3.08 45
2020 Q4 16,311,910 $58,071,014 -$3,250,489 $3.56 34
2020 Q3 17,216,699 $69,036,016 -$11,684,715 $4.01 33
2020 Q2 20,440,680 $55,598,011 -$392,205 $2.72 34
2020 Q1 20,651,240 $43,573,167 -$3,308,904 $2.11 36
2019 Q4 20,779,789 $113,038,430 -$10,373,847 $5.44 35
2019 Q3 22,891,685 $68,903,436 -$4,060,912 $3.01 34
2019 Q2 24,342,578 $90,952,754 -$1,503,000 $3.74 43
2019 Q1 24,763,106 $99,529,635 -$1,002,484 $4.02 56
2018 Q4 25,129,757 $92,163,767 -$1,838,747 $3.67 60
2018 Q3 25,496,765 $218,762,586 -$3,322,901 $8.58 60
2018 Q2 25,906,899 $284,454,314 +$6,770,964 $10.98 56
2018 Q1 25,285,587 $287,758,705 +$90,614,709 $11.53 54
2017 Q4 17,418,578 $180,457,571 -$3,160,000 $10.36 53
2017 Q3 17,544,055 $279,715,086 +$1,015,923 $15.94 52
2017 Q2 17,504,516 $211,804,598 -$2,803,453 $12.10 48
2017 Q1 17,335,240 $360,050,125 +$9,744,515 $20.77 52
2016 Q4 17,484,501 $250,048,615 +$17,391,608 $14.30 53
2016 Q3 16,266,787 $267,555,203 -$17,049,726 $16.45 44
2016 Q2 14,645,573 $208,464,147 +$13,774,406 $14.26 43
2016 Q1 13,758,120 $199,086,000 +$197,418,000 $14.50 31
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .